SELF-SUSTAINABLE TRIBOELECTRIC ENERGY CASE FOR POWERING DEVICES

    公开(公告)号:US20220140753A1

    公开(公告)日:2022-05-05

    申请号:US17520523

    申请日:2021-11-05

    Abstract: A power and/or electricity generating source and/or component that is TENG-based, and that may be configured as an assembly and/or component for powering one or more electronic devices, is disclosed, A case, carrier or other carrying container, for example a case for a cell phone, ipad, electronic tablet, personal computer, or any similar device, that provides an electricity source to power the cell phone, ipad, electronic tablet, is disclosed. The energy generating carriers and/or containers and configurations thereof, also provide an electricity energy storage source. This electronic energy storage source may be incorporated within an electronic device itself, or may be incorporated within the case and/or covering. Upon walking or touching a surface of an electronic device, the power generating source will harness mechanical energy, and provide for the generation of electricity with the one or more TENG components (TESTEC) that comprise the energy generating unit. Metal particles (silver, copper, etc. nanoparticles) incorporated within and/or on polymeric layers and/or a film of the carrier and/or container assembly, are also provided, and provide for enhanced energy generating capacity of the energy generating and storage components described.

    CMV neutralizing antigen binding proteins

    公开(公告)号:US11230591B2

    公开(公告)日:2022-01-25

    申请号:US16094624

    申请日:2017-04-18

    Abstract: The present invention is directed to antigen binding proteins including, but not limited to, monoclonal antibodies and antigen binding fragments thereof, that specifically bind to and preferably neutralize human cytomegalovirus (CMV). The antigen binding proteins of the invention are useful as a prophylactic and/or therapeutic agent for preventing and/or treating CMV infections in a patient in need thereof. Also encompassed by the invention are pharmaceutical compositions comprising the antigen binding proteins of the invention and a pharmaceutically acceptable carrier. The invention further relates to methods of using the antigen binding proteins and pharmaceutical compositions of the invention for the prevention or treatment of CMV infection in patients in need thereof.

Patent Agency Ranking